Category Archives: Immunology

Omalizumab Improves Lung Function in Adolescents With Uncontrolled Asthma – Pulmonology Advisor

Omalizumab may significantly improve lung function in adolescents with moderate to severe uncontrolled asthma, according to study results published in the Annals of Allergy, Asthma, and Immunology.

Omalizumab is a humanized monoclonal antibody against immunoglobulin E that was approved for the treatment of asthma in 2013 and has demonstrated significant improvement in lung function in adolescents in real-world studies. However, the effect of omalizumab on the lung function of adolescent patients in placebo-controlled trials has not been established. Therefore, researchers assessed the effect of omalizumab on lung function and eosinophil counts in adolescents aged 12 to 17 years with uncontrolled moderate to severe allergic asthma using a post-hoc analysis of 8 randomized trials. Of 340 adolescents, 203 received omalizumab and 137 received placebo.

Omalizumab increased all baseline lung function variables more than placebo by the end of the study (3.0% [P =.035], 120.9 mL [P =.009], and 101.5 mL [P =.033] for percent predicted forced expiratory volume in 1 second [FEV1], absolute FEV1, and forced vital capacity, respectively). In addition, the least squares mean difference demonstrated a greater reduction in eosinophil counts with omalizumab compared with placebo (P =.001).

The significant improvements in lung function observed in patients receiving omalizumab emphasize the potential effect of omalizumab in patients who remain uncontrolled on current therapies and the need to optimize treatment early in the disease course, the researchers concluded.

Disclosure: This clinical trial was supported by Genentech, Inc., a member of the Roche Group and Novartis Pharma AG. Please see the original reference for a full list of authors disclosures.

Reference

Busse WW, Humbert M, Haselkorn T, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma [published online November 21, 2019]. Ann Allergy Asthma Immunol. doi:10.1016/j.anai.2019.11.016

View post:
Omalizumab Improves Lung Function in Adolescents With Uncontrolled Asthma - Pulmonology Advisor

It Is the Time to Think About a Treat-to-Target Strategy for Knee Oste | TCRM – Dove Medical Press

A Migliore,1 G Gigliucci,1 RJ Petrella,2 RR Bannuru,3 X Chevalier,4 E Maheu,5 R Raman,6 G Herrero-Beaumont,7 N Isailovic,8 M Matucci Cerinc9

1Rheumatology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy; 2Department of Family Medicine, School of Kinesiology Western University, Western Centre for Public Health & Family, London, Ontario, Canada; 3Center for Treatment Comparison and Integrative Analysis Division of Rheumatology, Tufts Medical Center, Boston, MA, USA; 4Department of Rheumatology, Hpital Henri Mondor, Creteil, France; 5Rheumatology Department, AP-HP, Saint-Antoine Hospital, Paris, France; 6Academic Department of Orthopaedics, Hull and East Yorkshire NHS Trust, Castle Hill Hospital, Cottingham, UK; 7Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain; 8Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Milan, Italy; 9Division of Rheumatology AOUC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Correspondence: N IsailovicDivision of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Via A. Manzoni 56, Rozzano 20089, Milan, ItalyTel +39-02-8224-5118Email natasa.isailovic@humanitasresearch.it

Abstract: Osteoarthritis (OA) is a rheumatic disease that affects the well-being of the patient, compromises physical and mental function, and affects other quality of life aspects. In the literature, several evidence-based guidelines and recommendations for the management of knee osteoarthritis (KOA) are available. These recommendations list the different therapeutic options rather than addressing a hierarchy between the treatments and defining the real target. Therefore, a question arises: are patients and physicians satisfied with the current management of KOA? Actually, the answer may be negative, thus suggesting a change in our therapeutic strategies. In this article, we address this challenge by suggesting that it is time to develop a treat to target strategy for KOA.

Keywords: osteoarthritis, knee osteoarthritis, treat to target

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:
It Is the Time to Think About a Treat-to-Target Strategy for Knee Oste | TCRM - Dove Medical Press

Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines (Rheos), a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that it has entered into a worldwide exclusive collaboration, option and license agreement with Roche to discover, develop and commercialize novel therapeutics in the field of immunometabolism.

We are thrilled to be leveraging our expertise in human immune cell metabolism in partnership with Roche, said Barbara Fox, Chief Executive Officer of Rheos. We believe that our teams deep experience in immunology and cellular metabolism along with our unique approach have the potential to unlock a new frontier in precision medicine for immune mediated disease. This partnership will help to accelerate the translation of insights in immunometabolism to the development of groundbreaking therapeutics for patients with autoimmune and inflammatory diseases.

"We are excited to partner with Rheos and look forward to the development of a novel class of therapeutics for patients with autoimmune and inflammatory disease, said Gijs van den Brink, SVP and Global Head of Immunology, Infectious Diseases and Ophthalmology at Roche Pharma Early Research and Development. "We believe Rheos' proprietary platform and expertise in immunometabolism is a strong complement to Roche's expertise in autoimmunity and inflammation and in developing and commercializing innovative therapies."

Under the terms of the agreement, Rheos will conduct an exclusive research effort to identify novel targets in immunometabolism that modify the fate or function of certain human immune cells. In addition, Rheos will also be responsible for drug discovery efforts under the collaboration. Roche will receive an option to exclusively license a defined number of programs emerging from the collaboration. For certain products within the collaboration, Rheos and Roche could share worldwide development and US commercial rights.

Rheos will receive an upfront cash payment of $42.5 million upon execution and will be eligible to receive up to approximately $90 million for specified research and preclinical development milestones as well as option fees. Rheos will also be eligible to receive up to an additional approximately $660 million in specified development, regulatory and sales related milestones across the programs and tiered royalties on net sales. For those products for which Rheos and Roche could share development and commercial rights Rheos will be entitled to additional financial compensation within the US and ex- US commensurate with the share of its financial investment in development and commercialization.

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple omic datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit http://www.rheosrx.com.

Continue reading here:
Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism - Business Wire

A hero of the early days of AIDS – The Australian Jewish News

PROFESSOR Ron Penny, the man who diagnosed the first case of AIDS in Australia in 1982 and a leading researcher in the field, died overnight.

Penny and his family arrived in Australia in 1938 after fleeing the Nazis in Poland.It was that family history that defined in his career.

After diagnosing a gay man of having AIDS, he fought hard against the discrimination that followed in Australia.

The political issue was not AIDS itself; it was the discrimination and the repercussions of the way the straight community thought about gay men, Penny told The Sydney Morning Herald in the early 2000s.

The attitude was they caused it themselves, it is due to their lifestyle, and I saw that as a very dangerous process.

Being Jewish I think I understand discrimination my family left Poland because of the antisemitism and I could see that it was just the same story with different names.

Ron Penny (left), pictured with United Nations Special Commission chair Richard Butler.

Penny, who was St Vincents Hospitals Centre for Immunology inaugural director and went on to become one of Australias most influential scientists, made it his mission to defend the human rights of individuals.

I was trying to kill all those stories that you can get it from touching the handrail on a public bus, you can get it from going to the hairdressers, from gay men breathing on you or shaking hands.

Penny was honoured by many in his field and the community as a pioneer.

Don Baxter, the former head of the Australian Federation of AIDS Organisations said Penny was a strong leader and more than just a doctor in the early days of the AIDS epidemic.

He knew when to take risks and be publicly critical of the [health] minister commonwealth or state and when not to he was very much an activist.

Former federal health minister Neal Blewett said Penny was one of the heroes of the early days of HIV.

He was quite self-effacing and quite modest and I perhaps didnt realise how valuable he was.

Ron Penny, third from right, at a NSW Jewish Board of Deputies function to honour the St Vincents hospital.

In 2008, while chair of the NSW Governments Chronic, Aged and Community Health Priority task force, and a member of the NSW Health Care Advisory Committee, Penny was appointed to the Federal Governments National Health and Hospital Reform Commission

In 1993 the Commonwealth recognised Penny with an Officer of the Order of Australia (AO) for his service to medical research and education, particularly in the field of clinical immunology.

Get The AJN Newsletter by email and never miss our top storiesFree Sign Up

The rest is here:
A hero of the early days of AIDS - The Australian Jewish News

Cracking the Fever-Autism Mystery – Harvard Medical School

For many years, the parents of children with autism have reported that behavioral symptoms diminished when the child had a fever. The fever phenomenon has been documented in at least two large-scale studies over the past 15 years, but the reasons behind it have continued to mystify scientists.

Now, a new study by researchers at Harvard Medical School and MIT sheds light on the cellular mechanisms that appear to underlie this phenomenon.

In a study of mice, published Dec. 18 inNature, the researchers found that in some cases mimicking bacterial infection, an immune molecule called IL-17a is released and suppresses a small region of the brains cortex linked to social behavioral deficits in animal models.

Our findings finger the signaling cascade that leads to temporary alleviation of autism-like symptoms upon exposure to inflammatory conditions, highlighting the complex interplay between the nervous and immune systems in neurodevelopmental disorders such as autism, said study co-corresponding authorJun Huh, assistant professor of immunology in the Blavatnik Institute at HMS.

People have seen this phenomenon before [in people with autism], but its the kind of story that is hard to believe, which I think stems from the fact that we did not know the mechanism, saidGloria Choi, the Samuel A. Goldblith Career Development Assistant Professor of Applied Biology and an assistant professor of brain and cognitive sciences at MIT. Now the field, including my lab, is trying hard to show how this worksall the way from the immune cells and molecules to receptors in the brainand how those interactions lead to behavioral changes.

Although findings in mice do not always translate into humans, the study may help guide the development of strategies that could help reduce some behavioral symptoms of autism or other neurologic disorders, said Choi, who is also a faculty member of MITs Picower Institute for Learning and Memory.

The lead authors of the research are MIT graduate student Michael Douglas Reed and MIT postdoctoral fellow Yeong Shin Yim.

Immune influence

Choi and Huh previously explored other links between inflammation and autism. In 2016,they showedthat mice born to mothers who experience severe infections during pregnancy are much more likely to show behavioral symptoms such as deficits in sociability, repetitive behaviors and abnormal communication. They found these symptoms stem from exposure to maternal IL-17a, which produces defects in a specific brain region of the developing embryo. The brain region, S1DZ, is part of the somatosensory cortex and believed to be responsible for sensing where the body is in space.

Immune activation in the mother leads to very particular cortical defects, and those defects are responsible for inducing abnormal behaviors in offspring, Choi said.

A link between infection during pregnancy and autism in the offspring has also been documented in humans. A 2010 study that included children born in Denmark between 1980 and 2005 found that severe viral infections during the first trimester of pregnancy led to a threefold increase in risk for autism, and serious bacterial infections during the second trimester were linked with a 1.42-fold increase in risk. These infections included influenza, viral gastroenteritis and severe urinary tract infections.

In the new study, Choi and Huh turned their attention to the often-reported link between fever and reduction of autism symptoms.

We wanted to ask whether we could use mouse models of neurodevelopmental disorders to recapitulate this phenomenon, Choi said. Once you see the phenomenon in animals, you can probe the mechanism.

The researchers began by studying mice that exhibited behavioral symptoms due to exposure to inflammation during gestation. They injected these mice with a bacterial component called LPS, which induces a fever response, and found that the animals social interactions were temporarily restored to normal.

Further experiments revealed that during inflammation these mice produce IL-17a, which binds to receptors in S1DZthe same brain region shown to be affected by maternal inflammation. The experiments showed that IL-17a reduces neural activity in S1DZ, making mice temporarily more interested in interacting with fellow mice.

When researchers inhibited IL-17a or knocked out the receptors for IL-17a, mice did not experience a reversal of symptoms, a finding that pinpointed IL-17a as the responsible trigger. The experiments also showed that simply raising mices body temperature did not have any effect on behavior, offering further evidence that IL-17a is, indeed, the critical player behind reversal of symptoms.

This suggests that the immune system uses molecules like IL-17a to directly talk to the brain, and it actually can work almost like a neuromodulator to bring about these behavioral changes, Choi said. Our study provides another example as to how the brain can be modulated by the immune system.

Whats remarkable about this paper is that it shows that this effect on behavior is not necessarily a result of fever but the result of cytokines being made, said Dan Littman, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at New York University, who was not involved in the study. Theres a growing body of evidence that the central nervous system, in mammals at least, has evolved to be dependent to some degree on cytokine signaling at various times during development or postnatally.

Behavioral effects

The researchers then performed the same experiments in three additional mouse models of neurologic disorders. These mice lack a gene linked to autism and similar disorderseitherShank3,Cntnap2orFmr1. These mice all show deficits in social behavior similar to those of mice exposed to inflammation in the womb, even though the origin of their symptoms is different.

Injecting those mice with LPS did produce inflammation, but it did not have any effect on their behavior. The reason for that, the researchers found, is that in these mice, inflammation did not stimulate IL-17a production. However, if the researchers injected IL-17a into these mice, their behavioral symptoms did improve.

This suggests that mice who are exposed to inflammation during gestation end up with their immune systems somehow primed to more readily produce IL-17a upon exposure to other inflammatory conditions later in their life. Choi and Huh havepreviously shownthat the presence of certain bacteria in the gut can also prime IL-17a responses. They are now investigating whether the same gut-residing bacteria contribute to the LPS-induced reversal of social behavior symptoms that they found in the newNaturestudy.

Huh and Chois labs are also exploring whether any immune molecules other than IL-17a may affect the brain and behavior.

Whats fascinating about this communication is the immune system directly sends its messengers to the brain, where they work as if theyre brain molecules, to change how the circuits work and how the behaviors are shaped, Choi said.

It was amazing to discover that the same immune molecule, IL-17a, could have dramatically opposite effects depending on context: Promoting autism-like behaviors when it acts on the developing fetal brain and ameliorating autism-like behaviors when it modulates neural activity in the adult mouse brain, Huh said. This is the degree of complexity we are trying to make sense of.

The research was funded by the Jeongho Kim Neurodevelopmental Research Fund, Perry Ha, the Hock E. Tan and K. Lisa Yang Center for Autism Research, the Simons Center for the Social Brain, the Simons Foundation Autism Research Initiative, the Champions of the Brain Weedon Fellowship, and a National Science Foundation Graduate Research Fellowship.

Adapted from an MITnews release

Read more:
Cracking the Fever-Autism Mystery - Harvard Medical School

Bondada Named Fellow of the American Association for the Advancement of Science – UKNow

LEXINGTON, Ky. (Dec. 16, 2019) Subbarao Bondada, professor of microbiology in the Department of Microbiology,Immunology and Molecular Genetics in the University of Kentucky College of Medicine and Markey Cancer Center, has beennamed a Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers.

Bondada is being recognized for distinguished contributions to the field of immunology, particularly to studies of biology of normal and malignant B lymphocytes and antibody responses to bacterial polysaccharide antigens.

This year 443 members have been awarded this honor by AAAS because of their scientifically or socially distinguished efforts to advance science or its applications. New Fellows will be presented with an official certificate and a gold and blue (representing science and engineering, respectively) rosette pin on Saturday, Feb. 15at the AAAS Fellows Forum during the 2020 AAAS Annual Meeting in Seattle, Washington.

The tradition of AAAS Fellows began in 1874. Currently, members can be considered for the rank of Fellow if nominated by the steering groups of the associations 24 sections, or by any three Fellows who are current AAAS members (so long as two of the three sponsors are not affiliated with the nominees institution), or by the AAAS chief executive officer. Fellows must have been continuous members of AAAS for four years by the end of the calendar year in which they are elected. The AAAS Fellow honor comes with an expectation that recipients maintain the highest standards of professional ethics and scientific integrity.

Each steering group reviews the nominations of individuals within its respective section and a final list is forwarded to the AAAS Council, which votes on the aggregate list.

The Council is the policymaking body of the Association, chaired by the AAAS president, and consisting of the members of the board of directors, the retiring section chairs, delegates from each electorate and each regional division, and two delegates from the National Association of Academies of Science.

AAAS encourages its sections and Council to consider diversity among those nominated and selected as Fellows, in keeping with the associations commitment to diversity, equity and inclusion.

Visit link:
Bondada Named Fellow of the American Association for the Advancement of Science - UKNow

The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping – BioSpace

SOUTH SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation(NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab, a hub for collaborative and innovative research at the intersection of synthetic biology, protein engineering and personalized medicine, has chosen the Hyperion Imaging System to expand its capabilities in multiparameter imaging and immune profiling of tissue.

Building upon important research enabled by mass cytometry since 2016, the lab acquired a Hyperion Imaging System to expand its capabilities in multiparameter spatial analysis of the tissue microenvironment.

The Protein Assembly Lab is under the direction of Fei Wen, PhD, Associate Professor and Associate Chair for Undergraduate Education in Chemical Engineering, Director of the UM Mass Cytometry Core and Co-Director of the Immune Monitoring Shared Resource at the UM Rogel Cancer Center.

Our lab is exploring novel ways to push the field of precision health forward by engineering multiple protein assemblies into single entities that can act in an orchestrated and synergistic manner to carry out specific and sophisticated immunological functions to treat cancer and autoimmune disorders and to prevent viral infections, said Wen. We believe this approach could contribute to advances in a number of areas, including synthetic biology, cancer immunotherapy and immune phenotyping.

The Hyperion Imaging System enables us to extract a wealth of useful information from limited patient biopsy samples, which is critical to understanding patient-to-patient variability and developing novel and precise diagnostic and therapeutic reagents, Wen said.

Mass cytometry deeply profiles immune cell phenotypes and functions and is the basis of more than 900 research publications documenting workon the frontiers of immunology, immuno-oncology and other realms of health and disease. The addition of the Hyperion Imaging System extends the use of mass cytometry and is revolutionizing high-multiplex tissue analysis by deeply characterizing the tumor microenvironment with an efficient one-scan workflow.

We are truly excited that the University of Michigan Protein Assembly Lab has chosen the Hyperion Imaging System for critical research in a range of key areas including cancer immunotherapy and immune phenotyping, saidChris Linthwaite,FluidigmPresident and CEO. The University of Michigan is ranked number one in research volume among all U.S. public universities, and this is yet another example of the increasing adoption of our technology by premiere academic medical centers that are pioneering disease and therapy research innovation.

This commitment by the university also demonstrates the power of expanding research capabilities to include both suspension and imaging-based technology for more comprehensive analysis, supporting work with the potential to change the face of medicine, Linthwaite said.

About Fluidigm

Fluidigm(NASDAQ:FLDM) is an industry-leading biotechnology toolsprovider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, the Fluidigm logo, CyTOF, Hyperion, and Imaging Mass Cytometry are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding prospects for Fluidigm mass cytometry and Imaging Mass Cytometry products and the potential benefits of such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigms Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Media: Michaeline BuntingSenior Director, Marketing650 737 4190michaeline.bunting@fluidigm.com

See the original post here:
The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping - BioSpace

Strategic Assessment of Infectious Immunology Provides in-depth Analysis of Global Market 2019-2024 Poised to Expand at Progressive Rate | Top Players…

HealthCare Intelligence Markets has published a new report titled Infectious Immunology Market. Infectious Immunology involves studies of how the immune system responds to infectious agents and how infectious agents interact, modify or prevent the immune system. In recent years, there have been important advances in our understanding of the immune response to infection.

In order to provide an effective business outlook various global region such as North America, Latin America, Asia-Pacific, Europe and India have been examined. Major Key parameter of the businesses like profit margin, market shares and pricing structures have also been studied closely. To offer a clear understanding of Infectious Immunology Market various questions have been addressed in this analytical study concerning the progress of the businesses.

Ask for sample copy of this report at @ https://healthcareintelligencemarkets.com/request_sample.php?id=134517

Top Players profiled in this report Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientifics, Bio-Rad Laboratories, Dr. Reddys Laboratories and many more.

Primary and Secondary research methodologies have been used to scrutinize the different aspects of the businesses. In addition to this, it offers facts and figures on productivity across the various leading key players. Different influencing factors, which are driving or restraining the growth of the businesses have been studied to understand its upstream and downstream. Technological frameworks and effective tools are listed to give a clear approach to boost the performance of the companies.

Get Expected Discount on this report @ https://healthcareintelligencemarkets.com/ask_for_discount.php?id=134517

This statistical survey report offers numerous approaches to discover global opportunities for the rapid expansion of the business. It gives a comprehensive analysis of the Infectious Immunology Market which calculates different verticals of businesses such as, production capacity, local consumers, global and local clients and potential customers.

Furthermore, this research report has been aggregated on the basis of reliable analysis of dynamic aspects of the businesses. It presents a comparative analysis of Infectious Immunology companies to get extract information on resources and their effective utilization to achieve the desired outcome.

Table of Contents

Chapter 1 Infectious Immunology Market Overview

Chapter 2 Economic Impact on Industry

Chapter 3 Market Competition by Manufacturers

Chapter 4 Production, Revenue (Value) by Region

Chapter 5 Supply (Production), Consumption, Export

Chapter 6 Production, Revenue (Value), Price Trend by Type

Chapter 7 Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Market Forecast

Lastly, this report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market.

For more information ask our experts @ https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=134517

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

About HealthCare Intelligence Markets

90 State Office Center,

90 State Street Suite 700, Albany,

NY 12207

sales@healthcareintelligencemarkets.com

+1 (888) 616-2766

Read more:
Strategic Assessment of Infectious Immunology Provides in-depth Analysis of Global Market 2019-2024 Poised to Expand at Progressive Rate | Top Players...

Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company coupling targets selected based on causal human biology with structure-based drug discovery and development, today announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the companys Tyk2 subsidiary, Nimbus Lakshmi, Inc. In this role, Dr. Chen will provide executive leadership for financial, business, and development activities associated with the companys tyrosine kinase 2 (Tyk2) program, in addition to continuing her role as Chief Medical Officer for Nimbus Therapeutics.

Were at a very exciting juncture as Nimbus gears up to once again become a clinical-stage company, and there is no better person to helm that effort than Annie, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. Annies extensive background in immunology, her experience leading clinical strategy to bring multiple therapies forward to regulatory approval, and her passionate dedication as a clinician to the well-being of her patients will be of enormous value to our Tyk2 program as it advances into the clinic.

Tyk2 is a genetically validated target for the treatment of many autoimmune and inflammatory disorders, and through Nimbus structure-based drug discovery efforts, we have developed promising allosteric modulators that effectively inhibit this target, said Dr. Chen. Im honored to lead these multidisciplinary efforts for Nimbus as we initiate clinical studies and chart the programs future path.

Dr. Chen, who received her medical training as an adult rheumatologist, has served as Chief Medical Officer of Nimbus since 2015. She provided oversight for the companys acetyl CoA carboxylase clinical program for NASH and supported business development and financing efforts, before its acquisition by Gilead. Prior to joining Nimbus, Dr. Chen was Executive Director of Clinical Research, Section Head of Vaccines at Merck and Co., where she oversaw clinical research activities for a broad portfolio of vaccines, from discovery through registration and life cycle management. Dr. Chen also held the role of Section Head of Immunology, where she oversaw clinical research for small molecule and protein therapeutics. Prior to Merck, Dr. Chen held roles of increasing responsibility at Genentech, and began her career at Celera Genomics.

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and that have proven difficult for other drug makers to tackle. The companys LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. For more information, please visit http://www.nimbustx.com.

Read more here:
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company's Tyk2 Subsidiary - Business Wire

Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics – BioSpace

One of the central challenges of drug development has been bridging the gap between laboratory research in model organisms to meaningful clinical advances in humans, said Jeff Goldberg. Immunitas and our scientific co-founders use single cell genomic sequencing and sophisticated computational biology techniques to look at human biology directly. I believe this innovative approach can help to accelerate the development of new therapies for patients. I am excited to be joining the Immunitas team as we discover and develop these highly targeted new immuno-oncology therapies.

Immunitas identifies novel, promising oncology targets with potential applicability across both solid and liquid tumors. Additionally, as part of the discovery process, Immunitas develops key biomarkers to guide the selection of patients who may benefit from its new drugs. The company leverages its expertise in antibody discovery and engineering to create therapies that modulate these targets. Immunitas is currently advancing a number of programs toward early human studies, including a lead program with fully-human monoclonal antibodies that will be developed as single agents using a clinical biomarker strategy to guide early efficacy studies.

Jeff Goldberg has over 20 years of industry experience driving programs from discovery through all phases of drug development to commercialization in multiple therapeutic areas, including oncology, neurology, renal, and rare diseases, said Lea Hachigian, President and Director, Immunitas Therapeutics. We are fortunate to have his demonstrated ability leading and building teams as we create an oncology company powered by our human biology-focused approach to immunology.

Mr. Goldberg joins the Immunitas Board of Directors, which includes Dr. Laura Brass, Managing Director at Novartis Venture Fund, Dr. Jrgen Eckhardt, Head of Leaps by Bayer, Bayers strategic venture capital unit, Dr. Lea Hachigian, Principal, Longwood Fund, Dr. Lucio Iannone, Director of Venture Investments of Leaps by Bayer, Dr. Christoph Westphal, co-founder and General Partner of Longwood Fund, and Dr. Vincent Xiang, Managing Director at Hillhouse Capital.

Jeff Goldberg is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization in multiple therapeutic areas, including oncology, neurology, renal, and other rare and orphan diseases. Mr. Goldberg joins Immunitas from Akcea Therapeutics, where he was Chief Operating Officer from the time of its formation in January 2015. Previously, Mr. Goldberg was VP of Business Operations, leading both program management and business development at Proteostasis Therapeutics, Inc., a biotech company focusing on neurology and rare diseases. He also spent more than 11 years in positions of increasing responsibility with Genzyme and Sanofi, providing brand management for two marketed products within Sanofi Oncology. Prior to joining Sanofi Oncology, Mr. Goldberg served as Global Program Lead for Genzyme's stem cell mobilization agent Mozobil, leading the global launch team and overseeing the program management and marketing functions for the product. He began his career at Genzyme as Director, Program Management overseeing the development and launch of Renvela in patients undergoing dialysis. Mr. Goldberg has both an MBA and a Master's degree in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.

About Immunitas Therapeutics

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs. Lead programs from this platform have demonstrated single agent activity against challenging tumors and fully-human monoclonal antibodies are advancing towards clinical studies. http://www.ImmunitasTx.com.

Immunitas the human approach to oncology

View source version on businesswire.com: https://www.businesswire.com/news/home/20191218005153/en/

Excerpt from:
Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics - BioSpace